Thomas Marron, MD, PhD

img_Thomas Marron
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Cancer (Oncology)

PhD, Mount Sinai School of Medicine of New York University

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, Mount Sinai Hospital and Medical Center

Fellowship, Medical Oncology, Mount Sinai Hospital and Medical Center

Publications

Selected Publications

Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions. Malek Shatila, David Farris, Pankti Reid, Thomas U. Marron, Sophia C. Weinmann, Alexa S. Meara, Yinghong Wang. European Journal of Cancer

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. Pasquale Lombardi, Erik Ramon-Gil, Rabial Q. Raja, Leonardo Brunetti, Giulia Francesca Manfredi, Zhongguo Zhou, George Merces, Sarah Cappuyns, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas U. Marron, Anwaar Saeed, Matthias Pinter, Bernhard Scheiner, Yi Hsiang Huang, Pei Chang Lee, Naoshi Nishida, Ryan Po-Ting Lin, Andrea Dalbeni, Caterina Vivaldi, Gianluca Masi, Natascha Rohlen, Johann von Felden, Ahmed Kaseb, Peter R. Galle, Masatoshi Kudo, Wei Fan Hsu, Lorenza Rimassa, Alessandro Parisi, Robin Kate Kelley, Hidenori Toyoda, Mario Pirisi, Falah Jabar, Mehrdad Rakaee, Giuseppe Cabibbo, Calogero Cammà, Fabio Piscaglia, Sohyun Hwang, Dong Jun Shin, Michael Li, Jeroen Dekervel, Nadia Guerra, Tim Meyer, Helen L. Reeves, Bertram Bengsch, Gennaro Daniele, Derek A. Mann, Hong Jae Chon, Jack Leslie, David J. Pinato. Journal of Hepatology

Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer. Jonathan D. Spicer, Solange Peters, Justin F. Gainor, Jamie E. Chaft, Christine M. Bestvina, Jay M. Lee, Thomas U. Marron, Muhammad A. Khattak, Laureen S. Ojalvo, Joydeep K. Banerjee, Zheng Wang, Xuan Deng, Nazly Shariati, Steven M. Keller, Tina Cascone. Annals of Thoracic Surgery Short Reports

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Marron during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Astellas Pharma Inc.
  • Storm
  • AN2 Therapeutics, Inc.
  • Bayer Corporation
  • Evolveimmune
  • abdera
  • AbbVie Biotherapeutics, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim, Ltd.
  • Caris Life Sciences
  • EMD Serono, Inc
  • NTx Natures Toolbox
  • Pheast Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.